Renal Sympathetic Denervation Protects the Failing Heart Via Inhibition of Neprilysin Activity in the Kidney

• Published in: Journal of the American College of Cardiology 2017-10, Vol.70 (17), p.2139-2153
• Main Authors: Polhemus, David J., Trivedi, Rishi K., Gao, Juan, Li, Zhen, Scarborough, Amy L., Goodchild, Traci T., Varner, Kurt J., Xia, Huijing, Smart, Frank W., Kapusta, Daniel R., Lefer, David J.
• Format: Article
• Language: English
• Subjects: Ablation; Aminobutyrates - pharmacology; Angiotensin II - blood; Animals; Beta blockers; Bisoprolol - pharmacology; Blood Pressure; Cardiology; Cell injury; Coronary artery; Denervation; Drug Combinations; Echocardiography; Endothelium; Fibrosis; Heart; Heart diseases; Heart failure; Heart Failure - therapy; Kidney - innervation; Kidneys; Metabolism; Myocardium - chemistry; Myocardium - pathology; Neprilysin; Neprilysin - antagonists & inhibitors; Neprilysin - physiology; Nitrites - analysis; Norepinephrine - blood; Radio frequency; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Renal Artery - innervation; renal denervation; Renal function; Renal plexus; Renin - blood; Reperfusion; Reperfusion Injury - physiopathology; Rodents; Studies; Sympathectomy; Sympathetic nerves; sympathetic nervous system; Tetrazoles - pharmacology; vascular function; Vasodilators; Veins & arteries; Ventricle; Ventricular Function, Left - physiology
• ISSN: 0735-1097; 1558-3597
• DOI: 10.1016/j.jacc.2017.08.056

Sustained sympathetic activation contributes to the progression of myocardial cell injury, cardiac fibrosis, and left ventricular (LV) dysfunction in heart failure (HF). This study investigated the effects of radiofrequency renal nerve denervation (RF-RDN) on the pathobiology of HF and the interaction between the renal sympathetic nerves and natriuretic peptide (NP) metabolism. Spontaneously hypertensive rats (SHR) and normotensive Wistar-Kyoto rats (WKY) were subjected to 45 min of coronary artery ligation and reperfusion for 12 weeks. At 4 weeks post-reperfusion, SHR and WKY underwent either bilateral RF-RDN or sham-RDN. Following RF-RDN in both strains, LV ejection fraction remained significantly above those levels in respective sham-RDN rats, and at the end of the 12-week study, rats in both strains had significantly reduced LV fibrosis and improved vascular function. RF-RDN therapy significantly improved vascular reactivity to endothelium-dependent and -independent vasodilators as well as vascular compliance in the setting of severe HF. Improvements in LV function were accompanied by significant elevations in circulating NP as compared to those associated with sham-RDN. Further investigation into the cause of increased circulating NP levels demonstrated that RF-RDN significantly inhibited renal neprilysin activity in SHR and WKY with HF. Likewise, chronic treatment with the beta1 antagonist bisoprolol inhibited renal neprilysin activity and increased circulation NP levels in WKY with HF. This study identifies a novel endogenous pathway by which the renal nerves participate in the degradation of cardioprotective NP. Furthermore, removal of the influence of the renal nerves on kidney function attenuates renal neprilysin activity, augments circulating NP levels, reduces myocardial fibrosis, and improves LV function in the setting of HF. [Display omitted]